Download Sample
Add to CartGlobal Parathyroid Disorders Market Growth, Share, Size, Trends and Forecast (2025 - 2031)
By Type;
Simple Parathyroid Disorders and Complex Parathyroid Disorders.By Diagnosis;
Physical Examination, Laboratory Tests, and Electroencephalogram (EEG).By Treatment;
Home Management, Antipyretic Medication, and Others.By Distribution Channel;
Hospitals, Clinics, Diagnostic Centers, Drug Stores, Pharmacies, and Others.By Geography;
North America, Europe, Asia Pacific, Middle East and Africa, and Latin America - Report Timeline (2021 - 2031).Introduction
Global Parathyroid Disorders Market (USD Million), 2021 - 2031
In the year 2024, the Global Parathyroid Disorders Market was valued at USD 2194.04 million. The size of this market is expected to increase to USD 3087.23 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 5.0%.
Parathyroid Disorders Market is subjected to a thorough assessment. This scrutiny meticulously examines various segments, dissecting prevalent trends and significant factors influencing the market's direction. An in-depth analysis of market dynamics, which includes drivers, restraints, opportunities, and challenges, is conducted to illuminate their collective impact on market trends. This analysis considers both inherent factors such as drivers and restraints and external factors like market opportunities and challenges. The current market study provides an outlook on the development of market in terms of revenue throughout the prognosis period.
Parathyroid disorders encompass a range of conditions primarily involving the overproduction or underproduction of parathyroid hormone (PTH), which is crucial in regulating calcium levels in the body. The most common parathyroid disorders include hyperparathyroidism, hypoparathyroidism, and parathyroid cancer, each presenting unique challenges and requiring specific diagnostic and therapeutic approaches.
Hyperparathyroidism, characterized by the excessive secretion of PTH, is the most prevalent parathyroid disorder. It is often classified into primary, secondary, and tertiary types, each with distinct etiologies and treatment protocols. Primary hyperparathyroidism, typically caused by benign tumors such as parathyroid adenomas, leads to hypercalcemia and associated complications like osteoporosis, kidney stones, and cardiovascular issues. Secondary hyperparathyroidism is frequently observed in patients with chronic kidney disease, resulting from prolonged hypocalcemia. Tertiary hyperparathyroidism, a progression of secondary hyperparathyroidism, involves autonomous PTH secretion despite correction of the underlying cause. Hypoparathyroidism, on the other hand, involves insufficient PTH production, leading to hypocalcemia and subsequent neuromuscular irritability, tetany, and cardiac complications. The management of hypoparathyroidism often includes calcium and vitamin D supplementation, but novel therapies, such as recombinant PTH, are gaining traction for more effective long-term management. Parathyroid cancer, a rare but aggressive malignancy, represents a small fraction of parathyroid disorders. The diagnosis and treatment of parathyroid cancer involve surgical intervention and careful monitoring, given its potential for recurrence and metastasis.
Global Parathyroid Disorders Market Recent Developments
-
In March 2021, BridgeBio Pharma declared the positive outcomes from its 2nd stage trial of its new drug encaleret. Regarding hypoparathyroidism treatments, the drug has shown immense effectiveness among patients with autosomal dominant hypocalcemia type 1.
-
The COVID-19 has impacted the healthcare sector harshly. While, clinical trials for the rare diseases are postponed through 2020 as priority was given to the development of lifesaving drugs, the market for hypoparathyroidism is projected to witness a short-term fall even during 2021.
Segment Analysis
The Global Parathyroid Disorders Market report offers a comprehensive analysis, segmented into several key categories. By Type, the market covers conditions such as hyperparathyroidism, hypoparathyroidism, and other parathyroid-related disorders. Each type is analyzed based on its prevalence, underlying causes, and treatment approaches, providing insights into the varying market demand for specific therapeutic solutions.
Segmentation by Diagnosis includes methods such as blood tests, imaging tests, and biopsies. These diagnostic tools are essential for identifying parathyroid dysfunction and determining the severity of the condition. Advances in diagnostic technologies are highlighted, showcasing their impact on early detection and accurate diagnosis.
The market is further segmented by Treatment, which encompasses surgical interventions, hormone replacement therapy, calcium supplements, and other medications. This segment evaluates the effectiveness and adoption of various treatments, as well as emerging therapies that aim to enhance patient outcomes.
By Distribution Channel, the report examines the roles of hospitals, specialty clinics, retail pharmacies, and online pharmacies in delivering treatments to patients. The analysis highlights trends in accessibility, convenience, and the growing reliance on digital channels for medication distribution.
The Geography segment analyzes the market across regions, including North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. Regional variations in healthcare infrastructure, disease prevalence, and treatment availability are explored to understand their influence on market growth and opportunities.
Global Parathyroid Disorders Segment Analysis
In this report, the Global Parathyroid Disorders Market has been segmented by Type, Diagnosis, Treatment, Distribution Channel, and Geography.
Global Parathyroid Disorders Market, Segmentation by Type
The Global Parathyroid Disorders Market has been segmented by Type into Simple Parathyroid Disorders and Complex Parathyroid Disorders.
Parathyroid Disorders and Complex Parathyroid Disorders, providing a detailed understanding of the various manifestations and treatment requirements within this field. Simple Parathyroid Disorders primarily encompass conditions that are more straightforward to diagnose and manage, such as primary hyperparathyroidism and hypoparathyroidism. Primary hyperparathyroidism, often caused by benign parathyroid adenomas, leads to excessive production of parathyroid hormone (PTH) and consequent hypercalcemia. The management of this condition typically involves surgical removal of the overactive gland(s), known as parathyroidectomy, which has a high success rate. Hypoparathyroidism, characterized by insufficient PTH production and resulting hypocalcemia, is generally managed with calcium and vitamin D supplementation to maintain normal calcium levels. These disorders are relatively well-understood, and their treatment protocols are well-established, contributing to their classification as simple parathyroid disorders.
Complex Parathyroid Disorders include conditions that present greater challenges in diagnosis and treatment, often involving more severe symptoms or underlying causes that complicate management. This category includes secondary and tertiary hyperparathyroidism, parathyroid cancer, and genetic disorders affecting parathyroid function. Secondary hyperparathyroidism, commonly associated with chronic kidney disease (CKD), results from prolonged hypocalcemia and necessitates a multifaceted treatment approach. Management strategies may include phosphate binders, vitamin D analogs, calcimimetics, and, in severe cases, surgical intervention. Tertiary hyperparathyroidism, an evolution of secondary hyperparathyroidism, is marked by autonomous PTH secretion and requires a combination of medical and surgical treatments to achieve optimal patient outcomes.
Parathyroid cancer, although rare, represents a significant component of complex parathyroid disorders. It is an aggressive malignancy that poses considerable diagnostic and therapeutic challenges. Treatment typically involves extensive surgical resection, often followed by adjuvant therapies to address potential recurrence or metastasis. The complexity of parathyroid cancer management underscores the necessity for specialized care and advanced therapeutic strategies. Moreover, genetic disorders such as familial isolated hyperparathyroidism (FIHP) and multiple endocrine neoplasia (MEN) syndromes fall under complex parathyroid disorders. These conditions often require genetic counseling, regular monitoring, and tailored treatment plans to address the multifactorial nature of their presentation and progression.
Global Parathyroid Disorders Market, Segmentation by Diagnosis
The Global Parathyroid Disorders Market has been segmented by Diagnosis into Physical Examination, Laboratory Tests, and Electroencephalogram (EEG).
Physical examination remains the initial and fundamental step in diagnosing parathyroid disorders. During this examination, healthcare providers assess symptoms such as fatigue, bone pain, and muscle weakness, which can indicate underlying parathyroid abnormalities. Palpation of the neck may reveal palpable masses, suggesting parathyroid adenomas or carcinoma. Additionally, the clinical history, including prior medical conditions and family history of endocrine disorders, guides the clinician in suspecting and further investigating parathyroid-related issues.
Laboratory tests are pivotal in the accurate diagnosis and monitoring of parathyroid disorders. Serum calcium and PTH levels are the primary biochemical markers assessed. Elevated serum calcium coupled with increased PTH levels typically indicate primary hyperparathyroidism, while low calcium and low PTH suggest hypoparathyroidism. Secondary hyperparathyroidism is characterized by elevated PTH in response to low serum calcium, often due to chronic kidney disease. Moreover, 24-hour urinary calcium excretion tests help differentiate between familial hypocalciuric hypercalcemia and primary hyperparathyroidism. Advanced laboratory techniques, including genetic testing, are increasingly employed to identify hereditary conditions such as multiple endocrine neoplasia (MEN) syndromes, which predispose individuals to parathyroid disorders.
Electroencephalogram (EEG), though less commonly associated with parathyroid disorder diagnostics, holds significant relevance, particularly in severe hypocalcemia cases where neurological symptoms predominate. EEG can detect abnormal brain activity caused by low calcium levels, manifesting as seizures, which are a severe complication of hypoparathyroidism. The use of EEG in this context aids in the timely identification of neurological involvement, guiding urgent therapeutic interventions to restore calcium levels and stabilize the patient. The integration of these diagnostic modalities enhances the accuracy of parathyroid disorder diagnoses. Physical examinations provide a preliminary assessment, prompting further laboratory investigations that confirm and characterize the disorder. The role of EEG, while specialized, ensures comprehensive care in acute settings. This multi-faceted diagnostic approach reflects the complexity of parathyroid disorders, necessitating a thorough and methodical evaluation to ensure effective management.
Global Parathyroid Disorders Market, Segmentation by Treatment
The Global Parathyroid Disorders Market has been segmented by Treatment into Home Management, Antipyretic Medication, and Others.
Home management of parathyroid disorders is a crucial aspect, especially for patients dealing with chronic conditions like hypoparathyroidism or secondary hyperparathyroidism. This segment encompasses lifestyle modifications, dietary adjustments, and the use of supplements such as calcium and vitamin D. Patients are often educated on monitoring their symptoms and maintaining optimal calcium levels through routine blood tests. The ease of access to over-the-counter supplements and the growing trend of patient self-management are driving factors for the home management segment, reflecting a significant share of the market. Additionally, advancements in telemedicine and remote patient monitoring technologies have further enhanced the efficacy and convenience of home management strategies.
Antipyretic medication, although not a primary treatment for parathyroid disorders, plays a supportive role, particularly in managing symptoms associated with parathyroid disease complications. For instance, patients with severe hypercalcemia due to primary hyperparathyroidism may experience fevers and require antipyretic interventions to alleviate discomfort. This segment includes the use of nonsteroidal anti-inflammatory drugs (NSAIDs) and other fever-reducing agents that help manage the systemic symptoms associated with parathyroid imbalances. While antipyretic medication may not address the root cause of parathyroid disorders, its role in improving patient comfort and quality of life is undeniably significant.
Global Parathyroid Disorders Market, Segmentation by Distribution Channel
The Global Parathyroid Disorders Market has been segmented by Distribution Channel into Hospitals, Clinics, Diagnostic Centers, Drug Stores, Pharmacies, and Others.
Hospitals represent a significant segment within the parathyroid disorders market, driven by their comprehensive diagnostic and therapeutic capabilities. Hospitals are often the first point of care for patients with severe symptoms or complications arising from parathyroid disorders. They provide advanced diagnostic facilities such as imaging and biochemical tests, and offer a wide range of treatment options including surgery, which is critical for conditions like primary hyperparathyroidism and parathyroid cancer. Additionally, hospitals are equipped to manage complex cases requiring multidisciplinary approaches, involving endocrinologists, surgeons, radiologists, and other specialists.
Clinics, particularly endocrinology and specialty clinics, form another crucial segment. These facilities are typically involved in the long-term management of parathyroid disorders, providing continuous monitoring and follow-up care. Clinics play a vital role in adjusting treatment plans, managing medications, and offering lifestyle and dietary advice to patients. The personalized care and convenience offered by clinics make them an essential distribution channel, particularly for chronic conditions like hypoparathyroidism, where ongoing management is necessary.
Diagnostic centers are instrumental in the early detection and accurate diagnosis of parathyroid disorders. These centers specialize in a variety of diagnostic tests, including blood tests to measure calcium and PTH levels, as well as imaging techniques like ultrasounds, sestamibi scans, and MRIs. The precision and reliability of diagnostic centers contribute significantly to the effective management of parathyroid disorders by ensuring timely and accurate diagnosis, which is critical for the selection of appropriate therapeutic interventions. Drug stores and pharmacies are integral to the distribution of medications prescribed for the treatment of parathyroid disorders. These include calcium and vitamin D supplements, bisphosphonates, calcimimetics, and newer agents like recombinant PTH. The accessibility of drug stores and pharmacies ensures that patients can easily obtain their medications, which is crucial for adherence to treatment regimens and overall disease management. Moreover, pharmacies often provide additional services such as patient counseling, medication management, and adherence support, enhancing the overall quality of care.
Global Parathyroid Disorders Market, Segmentation by Geography
In this report, the Global Parathyroid Disorders Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
Global Parathyroid Disorders Market Share (%), by Geographical Region, 2024
The Americas lead the global parathyroid disorders market, primarily due to the increasing prevalence of parathyroid conditions and substantial healthcare expenditure. In 2015, the Centers for Disease Control and Prevention (CDC) reported that total health expenditure in the United States reached USD 3.2 trillion, with hospital care comprising 32.3% of this amount. This substantial investment in healthcare infrastructure and services facilitates the effective diagnosis and treatment of parathyroid disorders, ensuring better patient outcomes and driving market growth in the region. Additionally, the availability of advanced medical technologies and a strong focus on research and development further support the dominance of the Americas in this market.
Europe holds the second largest share in the global parathyroid disorders market. Government support for research and development initiatives, coupled with improvements in healthcare reimbursement policies, plays a crucial role in fostering market growth in this region. European governments have been proactive in funding research projects and enhancing healthcare systems to ensure comprehensive care for patients with parathyroid disorders. These measures not only improve the accessibility and quality of healthcare but also encourage the adoption of innovative diagnostic and therapeutic solutions. As a result, Europe continues to make significant strides in the management and treatment of parathyroid disorders, solidifying its position in the global market.
The Asia-Pacific region is the fastest-growing market for parathyroid disorders, driven by a large patient pool and advancements in healthcare technology. Several countries in this region are experiencing improvements in healthcare expenditure, which is facilitating better access to medical care and treatment options. For instance, according to the Australian Institute of Health and Welfare, the total health expenditure in Australia for the years 2015-2016 was USD 170.4 billion, marking a 3.6% increase from the previous year. This upward trend in healthcare spending reflects the region's commitment to enhancing healthcare infrastructure and services. The Asia-Pacific region's rapid economic growth and increasing awareness of parathyroid disorders are further contributing to the expansion of the market.
Market Trends
This report provides an in depth analysis of various factors that impact the dynamics of Global Parathyroid Disorders Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.
Drivers, Restraints and Opportunity Analysis
Drivers
- Increasing Prevalence of Parathyroid Disorders
- Advancements in Medical Research and Technology
-
Improving Healthcare Infrastructure- Enhanced infrastructure encompasses physical facilities, technological capabilities, and healthcare delivery systems, all of which play crucial roles in advancing the care of patients with parathyroid disorders. Upgraded healthcare infrastructure translates into better access to diagnostic tools and facilities. Modern imaging technologies such as high-resolution ultrasound, sestamibi scans, and MRI play a fundamental role in accurately locating parathyroid lesions and tumors, aiding in precise surgical planning and reducing procedural risks. Improved access to these diagnostic modalities enables earlier detection of parathyroid disorders, leading to timely intervention and improved patient outcomes.
Furthermore, robust healthcare infrastructure supports the implementation of advanced surgical techniques. Minimally invasive procedures, such as focused parathyroidectomy using techniques like intraoperative PTH monitoring and robotic-assisted surgery, reduce recovery times, minimize complications, and enhance patient satisfaction. These advancements not only improve surgical outcomes but also contribute to overall healthcare efficiency by reducing hospital stays and associated costs. In addition to diagnostics and surgery, comprehensive healthcare infrastructure supports the availability and administration of pharmacological therapies for parathyroid disorders. This includes medications such as calcimimetics for managing hyperparathyroidism and calcium and vitamin D supplements for hypoparathyroidism. Access to reliable pharmaceutical distribution channels, such as hospitals, clinics, and pharmacies, ensures that patients receive timely and appropriate medications, thereby supporting effective disease management.
Improved healthcare infrastructure facilitates multidisciplinary care coordination for patients with complex parathyroid disorders. Specialized clinics and centers of excellence equipped with the necessary infrastructure and expertise enable collaboration among endocrinologists, surgeons, radiologists, and other healthcare professionals. This collaborative approach ensures comprehensive evaluation, personalized treatment plans, and ongoing monitoring to optimize patient outcomes. Beyond clinical care, enhanced healthcare infrastructure also supports patient education and awareness initiatives. Well-equipped healthcare facilities can conduct outreach programs, educational seminars, and screening campaigns to increase public awareness about parathyroid disorders, symptoms, and preventive measures. Better informed patients are more likely to seek timely medical attention, leading to earlier diagnosis and intervention.
Restraints
- Scarcity of Specialized Healthcare Professionals
- Intellectual Property and Patent Issues
-
Side Effects and Complications of Treatments- Surgical interventions, such as parathyroidectomy for hyperparathyroidism or parathyroid cancer, carry risks such as injury to nearby structures (nerves, blood vessels), bleeding, infection, and the rare possibility of developing hypoparathyroidism if all parathyroid glands are inadvertently damaged or removed. These complications can prolong recovery times and necessitate ongoing medical management. Pharmacological treatments, including calcium supplements, vitamin D analogs, and medications like bisphosphonates or calcimimetics, also pose risks. Calcium and vitamin D supplements may lead to hypercalcemia if not monitored closely, while bisphosphonates can cause gastrointestinal discomfort and atypical femoral fractures with prolonged use.
Calcimimetics, although effective in controlling calcium levels, may result in nausea, vomiting, and hypocalcemia if dosages are not carefully adjusted. Moreover, for patients with hypoparathyroidism, maintaining optimal calcium and vitamin D levels can be challenging, often requiring frequent adjustments in medication dosages to prevent symptoms of hypocalcemia such as muscle cramps, spasms, and seizures. Beyond treatment-specific risks, managing parathyroid disorders involves addressing underlying conditions like chronic kidney disease or endocrine disorders, which themselves can complicate treatment outcomes.
Opportunities
- Technological Advancements in Diagnostics and Treatment
- Government and Private Sector Initiatives
-
Telemedicine and Remote Monitoring- These technologies enable healthcare providers to deliver timely and efficient care to patients with parathyroid disorders, regardless of geographical location. For patients in remote or underserved areas, telemedicine platforms allow access to specialized healthcare professionals who can provide consultations, monitor treatment progress, and adjust management plans as needed. This accessibility is particularly crucial for parathyroid disorders, where ongoing monitoring of calcium and parathyroid hormone levels is essential for disease management.
Remote monitoring devices, such as wearable sensors and home monitoring kits, enable patients to regularly track their health parameters and transmit data to healthcare providers in real-time. This capability not only improves patient engagement and adherence to treatment but also allows for early detection of potential complications or deviations from treatment goals. For instance, patients with hypoparathyroidism can use devices to monitor their calcium levels and adjust their medication dosages under medical guidance, reducing the risk of hypocalcemic episodes. Moreover, telemedicine facilitates multidisciplinary care coordination among endocrinologists, surgeons, primary care physicians, and other specialists involved in the management of parathyroid disorders. Virtual consultations and teleconferences enable healthcare teams to collaborate seamlessly, share diagnostic information, discuss treatment plans, and provide comprehensive care to patients. This integrated approach enhances treatment outcomes, reduces healthcare costs associated with unnecessary hospital visits, and improves overall patient satisfaction.
In addition to improving access to care, telemedicine and remote monitoring technologies contribute to the efficiency of healthcare delivery by reducing waiting times for appointments and optimizing healthcare resources. Patients benefit from more convenient access to healthcare services, while healthcare providers can streamline workflows and allocate resources more effectively. Furthermore, the adoption of telemedicine and remote monitoring aligns with global trends towards patient-centered care and personalized medicine. By leveraging these technologies, healthcare providers can tailor treatment plans based on individual patient data, including real-time health metrics and patient-reported outcomes. This personalized approach improves treatment efficacy, enhances patient empowerment, and ultimately contributes to better long-term management of parathyroid disorders.
Competitive Landscape Analysis
Key players in Global Parathyroid Disorders Market include:
- Abbott Laboratories
- Alcon Laboratories
- Amgen
- Bayer Healthcare
- Becton
- Dickinson and Company
- Eli Lilly
- Ethicon
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Type
- Market Snapshot, By Diagnosis
- Market Snapshot, By Treatment
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Global Parathyroid Disorders Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
-
Increasing Prevalence of Parathyroid Disorders
-
Advancements in Medical Research and Technology
-
Improving Healthcare Infrastructure
-
- Restraints
-
Scarcity of Specialized Healthcare Professionals
-
Intellectual Property and Patent Issues
-
Side Effects and Complications of Treatments
-
- Opportunities
-
Technological Advancements in Diagnostics and Treatment
-
Government and Private Sector Initiatives
-
Telemedicine and Remote Monitoring
-
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Global Parathyroid Disorders Market, By Type, 2021 - 2031 (USD Million)
- Simple Parathyroid Disorders
- Complex Parathyroid Disorders
- Global Parathyroid Disorders Market, By Diagnosis, 2021 - 2031 (USD Million)
- Physical Examination
- Laboratory Tests
- Electroencephalogram (EEG)
- Global Parathyroid Disorders Market, By Treatment, 2021 - 2031 (USD Million)
- Home Management
- Antipyretic Medication
- Others
- Global Parathyroid Disorders Market, By Distribution Channel, 2021 - 2031 (USD Million)
- Hospitals
- Clinics
- Diagnostic Centers
- Drug Stores
- Pharmacies
- Others
- Global Parathyroid Disorders Market, By Geography, 2021 - 2031 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- South Korea
- ASEAN (Association of South East Asian Countries)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Global Parathyroid Disorders Market, By Type, 2021 - 2031 (USD Million)
- Competitive Landscape
- Company Profiles
- Abbott Laboratories
- Alcon Laboratories
- Amgen
- Bayer Healthcare
- Becton
- Dickinson and Company
- Eli Lilly
- Ethicon
- Company Profiles
- Analyst Views
- Future Outlook of the Market